Peptide allergens and excipients reference

A patient injects a peptide and within twenty minutes develops a red, raised wheal that spreads across the forearm and shoulder. The clinician faces a triage question with several answers behind it. Is this an IgE-mediated immediate hypersensitivity to the peptide itself? An injection-site reaction driven by the vehicle — propylene glycol, phenol, m-cresol, polysorbate — sitting in the formulation alongside the active drug? A delayed-type cellular reaction surfacing hours after the actual dose? The endotoxin-mediated pyrogenic cascade documented for research-channel material whose chemistry-and-controls dossier does not include bacterial-endotoxin testing? The four answers point at different biology, different workup, and different management — and getting the triage wrong is one of the more common errors that ends up in case reports of "peptide allergy" that turn out to be something else.

This reference walks the allergen and excipient layer underneath every peptide product on this site: the immunological taxonomy of hypersensitivity reactions, the excipient composition of FDA-approved peptides whose package inserts publish that information, the allergen profiles that map to known patient sensitivities (latex, propylene glycol, polysorbate, m-cresol, benzyl alcohol, cyclodextrin), rare cross-reactivities (calcitonin and salmon allergy being the canonical example), the clinical workup of suspected peptide hypersensitivity, and the per-product excipient table that makes the framework operational. It sits alongside the peptide storage and stability technical reference, the peptide manufacturing technical reference, and the peptide injection technique reference. The audience splits three ways: clinicians evaluating a reaction need the differential and per-product excipient list; patients with a known allergy (shellfish, latex, polysorbate from a vaccine, propylene glycol from a topical) need the per-product mapping; anyone troubleshooting an unexpected reaction needs the framework distinguishing peptide-driven from excipient-driven from vehicle from technique from endotoxin contamination. The frame is educational. No therapeutic claims are made. Specific vendors are not named.

1. The framework — four categories of reaction

The clinical taxonomy that separates the differential at the bedside has four buckets that map to distinct underlying biology.

True immune-mediated hypersensitivity is the Gell and Coombs classification first articulated in 1963 and revised across the subsequent six decades (Rajan, Trends Immunol 2003, 24:376–379 for the modern re-interpretation). Type I is IgE-mediated immediate hypersensitivity — mast-cell and basophil degranulation within minutes of allergen exposure, producing urticaria, angioedema, bronchospasm, and at the severe end of the spectrum anaphylaxis. Type II is antibody-mediated cytotoxicity through IgG or IgM binding to a cell-surface antigen. Type III is immune-complex-mediated, with circulating antigen-antibody complexes depositing in tissues and activating complement — the classic mechanism behind serum sickness and certain drug-induced vasculitides. Type IV is T-cell-mediated delayed hypersensitivity, surfacing hours to days after exposure rather than minutes, producing the contact-dermatitis pattern and the granulomatous injection-site reactions documented for several subcutaneous peptide products.

Non-immune-mediated intolerance captures reactions that look clinically like allergy but do not involve adaptive immune memory. The canonical example is the anaphylactoid reaction to polysorbate 80 documented by Coors et al., Ann Allergy Asthma Immunol 2005, 95:593–599 — a severe reaction in a patient receiving an intravenous multivitamin product where polysorbate-specific IgE could not be identified despite the clinical picture, and the underlying mechanism was direct mast-cell activation by the excipient rather than classical type-I sensitization. Non-immune reactions can recur on first exposure (true allergy generally requires prior sensitization), are not typically associated with progressive severity on re-exposure, and respond to standard anaphylaxis treatment but do not require the lifelong-avoidance counseling that classical type-I allergy does.

Injection-site reactions are the most common category by incidence and often the most difficult to triage. Most are local and slow — erythema, induration, pruritus, mild swelling at the injection site, peaking hours after the injection and resolving over one to several days. The driver may be the peptide itself, the excipient profile, the vehicle, the injection technique, or some combination. The Vyleesi prescribing information reports injection-site reactions in approximately 13% of patients (Vyleesi PI, 2019) and they are the second-most-common adverse event in the GLP-1 receptor agonist class. The clinical signature that escalates the workup from "local reaction" to "type IV hypersensitivity" is recurrence at every injection site, progression over time, and a histopathology consistent with cellular infiltrate rather than mechanical irritation.

Excipient-mediated effects are the category most often missed in the initial workup. A patient who reacts to one product but tolerates a molecularly identical product with a different excipient profile has not reacted to the peptide — they have reacted to the formulation. The clinical illustration that breaks this open is the literature on liraglutide hypersensitivity with subsequent tolerance to semaglutide despite the two molecules sharing 97% sequence identity (Lipari et al., JAAD Case Rep 2023, 38:81–84; Calle Sarmiento et al., Cureus 2024, 16:e60879 for the parallel case series). The two products share propylene glycol as a vehicle component but differ in the specific formulation matrix, and the cross-reactivity pattern between them is not always what sequence homology predicts.

Most peptide reactions are not the peptide itself. The peptide is the molecule with regulatory and pharmacological attention; the excipient is the molecule that drives the reaction in the larger fraction of cases. The corollary is that the differential workup should map both the peptide and the excipient profile, not just the peptide.

2. The common excipient classes in peptide products

Peptide formulations carry an excipient matrix that varies by product, manufacturer, and route. The categories that matter for the hypersensitivity differential are preservatives, stabilizers, buffers, vehicles, and the cyclic and polymer carriers that appear in specific products.

Preservatives

Benzyl alcohol is the most common antimicrobial preservative in multi-dose injectable peptide preparations. The Pfizer-Hospira bacteriostatic water for injection product is 0.9% (9 mg/mL) benzyl alcohol — the standard diluent for practitioner-protocol multi-dose vial reconstitution across the research-channel field. Benzyl alcohol also appears in the multi-dose vial and KwikPen formulations of tirzepatide Mounjaro and Zepbound and in the Forzinity (elamipretide) product. Adult hypersensitivity is uncommon but documented; the load-bearing concern is the neonatal "gasping syndrome" described by Gershanik et al., N Engl J Med 1982, 307:1384–1388 — metabolic acidosis, encephalopathy, gasping respirations, intraventricular hemorrhage, and death in premature infants exposed to benzyl alcohol-preserved products, attributable to benzoic-acid metabolite accumulation that neonatal hepatic conjugation cannot clear. Section 6 addresses the syndrome in more detail.

Phenol is the antimicrobial preservative in the GLP-1 receptor agonist class: semaglutide Ozempic (5.50 mg/mL phenol), liraglutide Saxenda and Victoza (5.5 mg/mL phenol), and the multi-dose forms of tirzepatide Mounjaro and Zepbound. Wegovy is the GLP-1 outlier — the chronic-weight-management semaglutide formulation does not contain phenol or propylene glycol per the Wegovy prescribing information, which lists only disodium phosphate dihydrate, sodium chloride, and water for injection. Phenol hypersensitivity is documented in the dermatology literature but is not a common contributor to GLP-1 injection-site reactions.

m-Cresol (metacresol) is the antimicrobial preservative in insulin formulations and in several FDA-approved peptides: exenatide Byetta (2.2 mg/mL), pramlintide Symlin (2.25 mg/mL), and lixisenatide Adlyxin (8.1 mg/mL). The insulin-specific allergy literature documents delayed-type hypersensitivity to the m-cresol component itself — distinct from anti-insulin antibody development — with case reports of patients patch-testing positive to metacresol and negative to the insulin molecule (Rajpar and Shrestha, Contact Dermatitis 2006, 55:119–120; Carino et al., Ann Allergy Asthma Immunol 2007, 99:194–195). The workup that confirms m-cresol as the driver — patch testing with the excipient — is the canonical example of why the excipient-substitute trial is part of the standard differential.

Methylparaben and propylparaben appear in older preservation systems and in some compounded peptide preparations; they are not typical drivers of acute hypersensitivity at parenteral peptide doses.

Stabilizers and bulking agents

Mannitol is the dominant bulking agent across the lyophilized peptide field — the sugar alcohol that crystallizes cleanly under freeze-drying conditions, supports cake structure during sublimation, and provides the visible mass that a single-milligram peptide quantity alone cannot. Mannitol appears in Egrifta SV tesamorelin (20 mg/vial), Egrifta WR tesamorelin (43.5 mg/vial), exenatide Byetta, pramlintide Symlin, dulaglutide Trulicity (23.2 mg/dose), and sermorelin Geref (5 mg/vial in both 0.5 mg and 1.0 mg strengths). Mannitol is broadly inert; documented IgE-mediated hypersensitivity exists but is rare. The mannitol concern in peptide formulations is largely theoretical at clinical doses.

Trehalose is the disaccharide that has displaced mannitol in some modern formulations. The Skytrofa (lonapegsomatropin-tcgd) product contains trehalose dihydrate as the primary stabilizer alongside a succinic-acid buffer and tromethamine for pH adjustment (Skytrofa PI, 2021). Trehalose hypersensitivity is documented but uncommon.

Sucrose is a lyoprotectant — protects the peptide during freeze-drying by maintaining the molecule's hydrogen-bonding network as water is removed. The Egrifta SV tesamorelin formulation contains 10 mg of sucrose per vial alongside the histidine buffer, mannitol, and polysorbate 20. Sucrose is broadly inert at parenteral doses.

Glycine is a non-buffer amino acid that occasionally appears as a tonicity adjuster or stabilizer in older peptide formulations. The Geref sermorelin formulation does not contain glycine despite older secondary-source claims; the Geref prescribing information lists mannitol and phosphate buffer.

Polysorbate 20 and polysorbate 80 are nonionic surfactants — polyoxyethylene-sorbitan fatty acid esters — that solubilize protein and peptide therapeutics, reduce interfacial denaturation at air-water and container-surface interfaces, and protect against aggregation during manufacturing, transport, and storage. The Egrifta SV tesamorelin formulation contains 0.05 mg of polysorbate 20 per vial; Trulicity dulaglutide contains 0.10 mg polysorbate 80 per dose; Bydureon exenatide extended-release contains 0.63 mg polysorbate 20 per dose. The Coors et al. 2005 paper documented polysorbate 80 as a cause of non-immune anaphylactoid reactions in a vitamin-product cohort, with the mechanism described as nonimmunologic mast-cell activation rather than classical type-I sensitization. The post-2020 mRNA-vaccine literature has extended polysorbate and polyethylene-glycol hypersensitivity into a distinct clinical entity, with cross-reactivity between PEG and polysorbate documented in a subset of patients sensitized to either (Stone et al., J Allergy Clin Immunol Pract 2019, 7:1533–1540; the JAIP endotyping work referenced in subsequent reviews). Patients with a documented polysorbate or PEG hypersensitivity reaction warrant review of the peptide-product excipient list before any new injectable is introduced.

Buffers

Phosphate buffers — disodium phosphate dihydrate and the monobasic and heptahydrate analogs — dominate the peptide pH-control space. Wegovy contains 1.42 mg/mL disodium phosphate dihydrate; Ozempic, Saxenda, and Victoza carry the same 1.42 mg/mL phosphate; Mounjaro and Zepbound use sodium phosphate dibasic heptahydrate; Geref sermorelin uses a phosphate buffer for pH adjustment. Phosphate hypersensitivity at the doses used in peptide formulations is not clinically meaningful.

Citrate is the alternative pH-control system in some formulations. Trulicity dulaglutide uses a citrate buffer with both citric acid anhydrous (0.07 mg/dose) and trisodium citrate dihydrate (1.37 mg/dose). Citrate-buffered injectables are associated with transient injection-site stinging in some patients — a non-immune effect that traces to the buffer rather than to the active drug.

Acetate appears as the pH-control system in the m-cresol-preserved class. Exenatide Byetta uses sodium acetate trihydrate and glacial acetic acid at pH 4.5; pramlintide Symlin uses acetate; lixisenatide Adlyxin uses sodium acetate trihydrate. Acetate hypersensitivity is not clinically significant at parenteral peptide doses.

Succinate is the buffer in the Skytrofa lonapegsomatropin product alongside trehalose and tromethamine.

Tris (tromethamine) appears in some research-formulation buffers and in the Skytrofa pH-adjustment system.

Vehicles and diluents

Sterile water for injection (SWFI) — pharmacopeial-grade water with no preservative, supplied in single-use ampoules or vials. The diluent for single-dose preparations and the preferred diluent for any peptide product reconstituted for immediate use.

Bacteriostatic water for injection — 0.9% benzyl alcohol-preserved water with a 28-day in-use stability window after first puncture per the Pfizer-Hospira labeling. The standard diluent for multi-dose peptide preparations in practitioner-protocol and 503A compounded preparations.

0.9% sodium chloride (normal saline) is occasionally used as a peptide diluent, primarily where the manufacturer has validated salt-form compatibility against ionic strength.

Glycerin — also known as glycerol — is a non-aqueous co-solvent and tonicity adjuster. Vyleesi bremelanotide contains 2.5% glycerin per the Vyleesi prescribing information; the multi-dose vial and KwikPen formulations of Mounjaro and Zepbound tirzepatide contain glycerin alongside benzyl alcohol and phenol; lixisenatide Adlyxin contains 54 mg/mL glycerol 85%. Glycerin hypersensitivity at parenteral doses is not clinically meaningful.

Propylene glycol is the non-aqueous co-solvent in Ozempic (14 mg/mL), Saxenda (14 mg/mL), and Victoza (14 mg/mL). Wegovy is the formulation that does not contain propylene glycol, which becomes clinically significant for patients with documented propylene-glycol contact sensitivity reacting to the diabetes formulation but tolerating the weight-management formulation. The published delayed-type hypersensitivity case literature for liraglutide identifies the active drug rather than propylene glycol in formal patch testing — propylene-glycol patch tests have generally read negative in cases where the liraglutide intradermal test reads positive — but the excipient remains in the differential and the per-product mapping matters for the workup (Lipari et al., JAAD Case Rep 2023, 38:81–84).

Specialty carriers

Hydroxypropyl betadex (hydroxypropyl-β-cyclodextrin, HPBCD) is the cyclodextrin solubilizing agent in the Egrifta WR tesamorelin extended-release reconstitution kit — 145 mg per vial alongside 43.5 mg mannitol per the Egrifta WR prescribing information. HPBCD is broadly characterized as a low-hypersensitivity excipient in the cyclodextrin literature (Stella and He, Toxicol Pathol 2008, 36:30–42 for the regulatory-pathology review), but vaccine and drug-product cohort data have surfaced rare hypersensitivity attributable to the cyclodextrin component rather than the active drug.

SNAC (salcaprozate sodium) is the absorption-enhancer in Rybelsus oral semaglutide alongside magnesium stearate, microcrystalline cellulose, and povidone per the Rybelsus prescribing information. SNAC transiently raises gastric pH locally and increases gastric epithelial permeability for the active drug; SNAC-specific hypersensitivity has not been reported as a meaningful clinical signal.

Poly(D,L-lactide-co-glycolide) (PLGA) is the biodegradable polymer carrier in Bydureon exenatide extended-release — 37.2 mg per dose, with the active drug encapsulated in microspheres that release the peptide gradually after subcutaneous injection. PLGA injection-site nodules and granulomas are documented for the Bydureon product, often persisting weeks-to-months at the injection site, distinct from the acute-reaction patterns seen with the smaller-molecule excipients.

Polyethylene glycol (PEG) in conjugates is a special case. Some peptide products use PEG carriers to extend half-life; anti-PEG antibodies — both treatment-induced and pre-existing in PEG-naive populations — are documented for many PEGylated therapeutics with clinical consequences including accelerated blood clearance, complement-activation-related pseudoallergy, and rare anaphylactoid reactions (Wei et al., Pharmaceutics 2025, 17:1074 on the contemporary review; Sellaturay et al., J Allergy Clin Immunol Pract 2019, 7:670–671 on the immunogenicity work). Lonapegsomatropin (Skytrofa) addresses this through a transient-conjugate design that releases unmodified somatropin into circulation rather than persisting as a PEG-protein conjugate; the design is intended to preserve the half-life-extension benefit while limiting persistent PEG exposure. The PEG question is product-specific and is the subject of the forthcoming pegylated-peptides-last-forever-myth critic response.

Disulfide bonds and cysteine-containing peptides carry their own chemistry rather than an excipient-driven concern. Peptides with disulfides — oxytocin, some Khavinson short peptides, LL-37 at the relevant pH — have native chemistry that interacts with thiol-containing co-administered medications and with the reducing conditions in some compounding processes. Hypersensitivity attributable to the disulfide bond rather than to the peptide as a whole is not a typical clinical signal.

3. Per-product excipient table

The table below compiles the labeled inactive-ingredient lists for the FDA-approved peptide products on this site, anchored in the prescribing information for each product. For the research-channel and gray-market peptides, no labeled excipient list exists; the practitioner-protocol reconstitution typically uses bacteriostatic water (0.9% benzyl alcohol) as the diluent and the dry-vial bulking agent depends on which manufacturer produced the specific lot.

Product (peptide)	Form	Preservative(s)	Buffer	Vehicle / co-solvent	Other excipients
Ozempic (semaglutide)	Pre-mixed pen, subq	Phenol (5.50 mg/mL)	Disodium phosphate dihydrate (1.42 mg/mL)	Propylene glycol (14.0 mg/mL); water for injection	None at clinically meaningful concentrations
Wegovy (semaglutide)	Pre-mixed pen, subq	None	Disodium phosphate dihydrate (1.42 mg/mL)	Sodium chloride (8.25 mg/mL); water for injection	None at clinically meaningful concentrations
Rybelsus (oral semaglutide)	Tablet, oral	None	None (tablet)	None	Magnesium stearate, microcrystalline cellulose, povidone, salcaprozate sodium (SNAC)
Saxenda (liraglutide)	Pre-mixed pen, subq	Phenol (5.5 mg/mL)	Disodium phosphate dihydrate (1.42 mg/mL)	Propylene glycol (14 mg/mL); water for injection	None at clinically meaningful concentrations
Victoza (liraglutide)	Pre-mixed pen, subq	Phenol (5.5 mg/mL)	Disodium phosphate dihydrate (1.42 mg/mL)	Propylene glycol (14 mg/mL); water for injection	None at clinically meaningful concentrations
Mounjaro (tirzepatide) — single-dose vial / pen	Pre-mixed, subq	None (single-dose)	Sodium phosphate dibasic heptahydrate (0.7 mg/dose)	Sodium chloride (4.1 mg/dose); water for injection	None at clinically meaningful concentrations
Mounjaro KwikPen / Zepbound KwikPen (tirzepatide) — multi-dose	Pre-mixed multi-dose pen, subq	Benzyl alcohol, phenol	Sodium phosphate dibasic heptahydrate	Sodium chloride; glycerin; water for injection	None at clinically meaningful concentrations
Byetta (exenatide)	Pre-mixed pen, subq	m-Cresol (2.2 mg/mL)	Sodium acetate trihydrate / glacial acetic acid (pH 4.5)	Water for injection	Mannitol (tonicity)
Bydureon BCise (exenatide ER)	Suspension, subq	None	Sodium phosphate monobasic / dibasic	Carboxymethylcellulose sodium (19 mg); water for injection	Polysorbate 20 (0.63 mg); sodium chloride (4.1 mg); PLGA microspheres (37.2 mg); sucrose (0.8 mg)
Symlin (pramlintide)	Pre-mixed pen, subq	m-Cresol (2.25 mg/mL)	Sodium acetate / acetic acid	Water for injection	D-mannitol (tonicity)
Adlyxin (lixisenatide)	Pre-mixed pen, subq	m-Cresol (8.1 mg/mL)	Sodium acetate trihydrate (10.5 mg/mL)	Glycerol 85% (54 mg/mL); water for injection	L-methionine (9.0 mg/mL) — antioxidant
Trulicity (dulaglutide) — GLP-1 class	Pre-mixed pen, subq	None	Citric acid anhydrous (0.07 mg) + trisodium citrate dihydrate (1.37 mg)	Water for injection	Mannitol (23.2 mg); polysorbate 80 (0.10 mg)
Egrifta SV (tesamorelin)	Lyophilized, subq	None (single-dose, reconstituted with SWFI)	Histidine (0.78 mg/vial)	Sterile water for injection (diluent)	Mannitol (20 mg); polysorbate 20 (0.05 mg); sucrose (10 mg)
Egrifta WR (tesamorelin)	Lyophilized, weekly-reconstituted, subq	None (single-patient-use vial)	None (HPBCD-based formulation; HCl / NaOH for pH)	Sterile water for injection (diluent)	Hydroxypropyl betadex (145 mg); mannitol (43.5 mg)
Geref (sermorelin) — historical	Lyophilized, subq	None	Dibasic / monobasic sodium phosphate	Sterile water for injection (diluent)	Mannitol (5 mg/vial)
Skytrofa (lonapegsomatropin)	Lyophilized dual-chamber pen, subq	None	Succinic acid; tromethamine (pH 5)	Water for injection (diluent)	Trehalose dihydrate; transient-conjugate 40 kDa mPEG carrier
Vyleesi (bremelanotide)	Pre-filled auto-injector, subq	None (single-dose)	None (HCl / NaOH for pH)	Sterile water for injection	Glycerin (2.5%)
Forzinity (elamipretide)	Multi-dose vial, subq	Benzyl alcohol (10 mg/0.5 mL dose)	Monobasic sodium phosphate (2.07 mg/dose, as monohydrate)	Water for injection	None at clinically meaningful concentrations
Miacalcin (calcitonin-salmon)	Multi-dose vial, subq / IM	Phenol (typical)	Acetate / sodium acetate	Water for injection	Sodium chloride (tonicity)
Bacteriostatic water for injection	Diluent	Benzyl alcohol (0.9% / 9 mg/mL)	None	Water for injection	None
Sterile water for injection (SWFI)	Diluent	None	None	Water for injection	None
0.9% sodium chloride	Diluent	None	None	Water for injection	Sodium chloride (9 mg/mL)

Compounded and research-channel peptides sit outside this framework by design — the certificate of analysis released with a research-channel batch does not characterize excipient composition the way a labeled prescribing information does. The peptide manufacturing technical reference addresses the broader chemistry-and-controls picture; the practical point for the hypersensitivity differential is that a reaction to a compounded peptide is typically reported with less excipient information than the FDA-approved-product reaction, and reconstructing the excipient profile from the lot record is often impossible after the fact.

4. Known allergens with cross-reactivity to peptide products

The cross-reactivity panel is narrower than the dermatology- and food-allergy literature might suggest.

Latex. Some injectable drug products historically used latex in pen plungers or vial stoppers. The contemporary trend across the FDA-approved peptide field is toward latex-free packaging — most modern auto-injectors and pens are now labeled latex-free — but patients with documented latex anaphylaxis should verify device labeling for each specific product. The decision is anchored in specific device labeling rather than a class-wide rule.

Iodine. Some preservation methods historically involved iodine-containing antiseptics. Modern peptide products do not contain iodine as a formulation component. The occasional patient-facing claim that "iodine-containing peptides" pose a risk to patients with shellfish allergy lacks meaningful chemistry — shellfish allergy is anchored in tropomyosin and parvalbumin protein epitopes, not iodine.

Shellfish and fish. Cross-reactivity between marine-protein allergens and peptide therapeutics is essentially nil for the synthetic peptide field — peptides are typically chemically synthesized via solid-phase peptide synthesis rather than derived from marine sources. The one classical exception is salmon calcitonin (Miacalcin and equivalents): the peptide sequence is derived from salmon, and rare anaphylaxis has been documented in patients with prior salmon allergy. The Miacalcin prescribing information carries a labeled hypersensitivity warning and recommends skin testing in patients with suspected sensitivity. Cross-reactivity is otherwise not a concern for the synthetic peptide field; GLP-1, GIP, BPC-157, and the rest of the corpus are synthetic and carry no marine-protein epitope.

Egg and soy. Some recombinant manufacturing processes use yeast or mammalian cell lines; egg and soy are not typical fermentation-media components for the peptide field, and the carry-over concern is more relevant for egg-cultured influenza vaccines than for peptide therapeutics. The peptide manufacturing technical reference addresses host-cell-protein testing for recombinant products.

Polysorbate / PEG cross-reactivity. The contemporary panel emerging from the post-2020 vaccine-allergy literature. A patient with a documented systemic reaction to an mRNA COVID vaccine (PEG-containing) or to a polysorbate-containing biologic warrants explicit excipient review for any new peptide. The clinically meaningful overlap covers products carrying polysorbate 80 (Trulicity dulaglutide), polysorbate 20 (Egrifta SV tesamorelin, Bydureon exenatide), and PEG carriers in conjugates. Cross-reactivity is not universal — most patients with one are not sensitized to the other — but the panel deserves the per-product check.

Cyclodextrin. Patients with documented cyclodextrin hypersensitivity should verify formulation for any product containing hydroxypropyl-β-cyclodextrin — for this corpus, Egrifta WR tesamorelin is the primary product to flag.

5. Hypersensitivity reactions to peptide therapeutics — clinical patterns

The reaction patterns span the full Gell and Coombs classification, with population-level rates anchored in post-marketing pharmacovigilance.

Type I — IgE-mediated immediate. Acute urticaria, angioedema, and at the severe end anaphylaxis, within minutes to a few hours of injection. The most rigorous population-level dataset is the Pradhan et al., Am J Epidemiol 2022, 191:1352–1367 multi-site cohort: anaphylactic reactions occurred at approximately 37 per 100,000 person-years across the GLP-1 receptor agonist class, compared with 32 per 100,000 for DPP-4 inhibitors and 29 per 100,000 for SGLT-2 inhibitors (HR vs. SGLT-2 ≈ 1.38). Case-report literature documents angioedema and anaphylaxis attributed to semaglutide (Hyman et al. 2023) and to tirzepatide (Lawrence et al. 2024). Clinical management follows Lieberman et al., Ann Allergy Asthma Immunol 2015, 115:341–384 — epinephrine as first-line, oxygen, IV fluids, and structured post-event evaluation.

Type IV — delayed cellular. Injection-site reactions hours-to-days post-injection are the most common peptide-field pattern by incidence. The liraglutide case literature (Lipari et al. 2023; Calle Sarmiento et al. 2024) walks the diagnostic confirmation: intradermal testing with the active drug reads positive at 24-hour evaluation, patch testing with the excipients reads negative or non-specific, and histopathology demonstrates lymphocytic infiltrate consistent with delayed-type cellular hypersensitivity rather than mast-cell-driven type-I pathology. Granuloma formation at the injection site is the chronic correlate, particularly documented for extended-release PLGA-encapsulated formulations. Cross-tolerance between liraglutide and semaglutide is variable despite the 97% sequence homology — the pattern is most consistent with epitope-level rather than molecule-level sensitization.

Type III — serum sickness. Rare; documented in the monoclonal-antibody class but uncommonly reported for the small-peptide field. The signature is delayed onset of fever, urticarial rash, arthralgia, lymphadenopathy with complement consumption. Not a typical concern for synthetic small peptides.

Anti-drug antibody development. Full pharmacology is in the antibody development chronic peptide therapy myth critic response. The summary for hypersensitivity: ADA can occasionally produce hypersensitivity-pattern reactions (immune-complex deposition, complement activation) but more commonly drives efficacy attenuation. The FDA-approved record shows binding-antibody development is common (47% for tesamorelin at week 52; 51% for tirzepatide across SURPASS), neutralizing-antibody development is rare, and clinical hypersensitivity specifically attributable to ADA is rarer still.

6. Excipient-mediated reactions — specific patterns

The excipient-driven reaction patterns that warrant the most clinical attention have their own pharmacology distinct from the peptide-driven mechanisms.

Benzyl alcohol gasping syndrome in neonates. Gershanik et al. 1982 anchors the contemporary contraindication. The mechanism is benzoic-acid accumulation from benzyl alcohol metabolism in an immature hepatic conjugation system, producing severe metabolic acidosis, encephalopathy, intraventricular hemorrhage, and death in premature infants exposed to multi-dose benzyl alcohol-preserved products. The clinical translation is unambiguous: bacteriostatic water for injection and benzyl alcohol-preserved peptide products are contraindicated in neonatal use. Adult exposures from peptide-vial reconstitution sit well below the toxic threshold.

Polysorbate 80 nonimmunologic anaphylactoid reactions. Coors et al. 2005 documented the index case; the 2020s vaccine-allergy literature extended the polysorbate and PEG hypersensitivity panel into the contemporary clinical workup (Stone et al. 2019; Kounis et al. 2023). Among the peptide products on this site, the polysorbate-containing formulations to flag are Trulicity dulaglutide (polysorbate 80), Egrifta SV tesamorelin (polysorbate 20), and Bydureon exenatide ER (polysorbate 20).

m-Cresol allergic reactions. Insulin-specific delayed-type hypersensitivity to m-cresol is the canonical example; case literature documents patch-test confirmation of m-cresol sensitization and successful tolerance to formulations using alternative preservatives (Carino et al. 2007; Rajpar and Shrestha 2006). The peptide products on this site that carry m-cresol are Byetta exenatide, Symlin pramlintide, and Adlyxin lixisenatide; a patient with documented m-cresol hypersensitivity should substitute a product with a different preservative system.

Cyclodextrin reactions. Hydroxypropyl-β-cyclodextrin is broadly low-hypersensitivity, but rare cyclodextrin-attributable reactions are documented. The peptide product on this site using hydroxypropyl betadex is Egrifta WR tesamorelin.

Propylene glycol. Cited as a possible GLP-1 injection-site trigger, but propylene-glycol patch testing in the published delayed-hypersensitivity literature has generally read negative when intradermal testing with the active drug reads positive. Patients with documented propylene-glycol contact sensitivity may tolerate Wegovy (propylene-glycol-free) better than Ozempic, Saxenda, or Victoza.

7. Clinical workup of suspected peptide hypersensitivity

The structured workup is anchored in the drug-allergy practice parameter literature (Solensky et al., Ann Allergy Asthma Immunol 2010, 105:259–273).

Characterize the reaction. Timeline (immediate within minutes vs. delayed within hours-to-days), distribution (local vs. systemic), pattern (urticarial, angioedema, anaphylactic, dermatitis, granuloma), and the specific product, lot, route, dose, and concurrent medications. First-exposure reactions are more likely to be non-immune anaphylactoid or excipient-mediated than classical type-I sensitization, which generally requires prior exposure for IgE class-switching.

Skin prick and intradermal testing. Skin prick testing with the suspected peptide and relevant excipients (polysorbate, PEG, propylene glycol, m-cresol) is the first-line in-vivo test for type-I hypersensitivity. Intradermal testing — with appropriately diluted peptide and excipient panels at 24-hour and 48-hour readings — is the more sensitive test for type-IV delayed reactions. The published GLP-1 case literature anchors intradermal testing with the active drug at 1:10 dilution as the canonical positive control for delayed reactions.

Specific IgE testing where commercially available. Specific IgE assays exist for some excipients (PEG, polysorbate) and some peptide therapeutics (insulin); availability varies by laboratory. A negative test does not rule out type-I sensitization, particularly for novel peptides without validated assays.

Patch testing for delayed reactions. Patch testing with the formulation, the active drug at appropriate dilution, and candidate excipients — read at 48 and 96 hours — is the canonical diagnostic for type-IV delayed cellular hypersensitivity.

Drug provocation testing. Under medical supervision in a setting equipped for anaphylaxis management, controlled re-exposure starting at low dose and escalating incrementally is the gold-standard diagnostic. The risk profile is non-trivial; provocation is appropriate when the clinical question requires resolution and the alternative is empirical avoidance of an indicated therapy.

Excipient-substitute trial. The most cost-effective workup in many cases. Reaction to a propylene-glycol-containing formulation (Ozempic, Saxenda, Victoza) → substitute the propylene-glycol-free analog (Wegovy). Reaction to an m-cresol-containing product (Byetta, Symlin, Adlyxin) → substitute a different preservative system. Reaction to a polysorbate-containing product → substitute a polysorbate-free option. Tolerance of the alternative confirms excipient-driven reaction; recurrence implicates the active drug or a shared excipient.

8. The differential at the bedside

A patient injects tirzepatide and within thirty minutes develops urticaria, mild angioedema, and a sensation of throat tightness. The differential, in order of investigation:

Is this anaphylaxis to the peptide itself? Type-I hypersensitivity to tirzepatide is documented but rare; the Pradhan et al. cohort places the GLP-1-class rate at approximately 37 anaphylactic reactions per 100,000 person-years. Acute management does not wait for diagnostic confirmation — epinephrine, oxygen, IV fluids per the Lieberman et al. 2015 anaphylaxis practice parameter. The diagnostic workup follows the acute management.

Is this an excipient-mediated reaction? Tirzepatide multi-dose KwikPen contains benzyl alcohol, phenol, sodium chloride, sodium phosphate dibasic heptahydrate, glycerin, and water for injection. The single-dose vial contains only sodium chloride, sodium phosphate, and water for injection. A reaction to the multi-dose product with later tolerance to the single-dose vial would implicate benzyl alcohol, phenol, or glycerin as the driver; a reaction to both implicates the active drug or a shared excipient.

Is this contamination? Specifically endotoxin. Endotoxin-mediated pyrogenic reactions present within two-to-six hours of injection with fever, chills, hypotension, and tachycardia — distinct from the immediate-hypersensitivity pattern. The endotoxin question is most relevant for compounded or research-channel peptide products whose chemistry-and-controls dossier does not include the bacterial-endotoxin test that pharmaceutical-grade release would require; the peptide manufacturing technical reference addresses this in detail.

Is this injection technique? Lipohypertrophy, inadvertent intramuscular injection at a thin-subcutaneous site, or a non-sterile needle introducing local infection produces a clinically distinct pattern from immune-mediated hypersensitivity. The peptide injection technique reference covers this layer.

Is this concurrent medication? Polypharmacy is the common confounder — a patient on ACE inhibitors with peptide-associated angioedema may have ACE-inhibitor-induced angioedema with peptide co-administration as the proximate trigger rather than the underlying cause. Medication reconciliation catches this.

Documentation and reporting. For FDA-approved products, the FDA MedWatch system accepts voluntary adverse-event reports from healthcare professionals (Form 3500) and from patients (Form 3500B). For research-channel peptides, the pharmacovigilance infrastructure is essentially absent — the FDA Adverse Event Reporting System (FAERS) does not have a clean denominator for compounded or research-channel peptide exposures. When a reaction occurs, document brand name, manufacturer, lot number, expiration date, reconstitution diluent, route, dose, site, and timing relative to other medications.

9. The honest framing

Peptide hypersensitivity is real, documented across the four Gell and Coombs categories, occurs at rates consistent with the broader drug-allergy population baseline, and is more often driven by the formulation excipient than by the peptide itself. Injection-site reactions are the dominant pattern by incidence; systemic immediate hypersensitivity is the dominant pattern by clinical urgency; delayed-type reactions are the most diagnostically subtle and the most likely to be misattributed to the active drug when an excipient is the actual driver.

For any patient with a reported "peptide allergy," the per-product excipient profile is the first stop, the excipient-substitute trial is often the most informative single diagnostic step, and the structured workup anchored in the drug-allergy practice parameter literature is the path that resolves the question rather than the empirical avoidance that often follows an unexamined first reaction. The table in Section 3 is the working reference; for the patient with a known excipient allergy (polysorbate, PEG, m-cresol, propylene glycol, benzyl alcohol, cyclodextrin, latex), the per-product mapping determines whether a given peptide product is a candidate or a contraindication. The storage and stability, manufacturing, and injection technique references cover adjacent layers; the antibody development chronic peptide therapy myth critic response covers the related immunogenicity question for chronic dosing.

Sources cited

External canonical and regulatory references verified for this reference:

• Gershanik et al., N Engl J Med 1982, 307:1384–1388 — The gasping syndrome and benzyl alcohol poisoning
• Rajan, Trends Immunol 2003, 24:376–379 — The Gell-Coombs classification of hypersensitivity reactions: a re-interpretation
• Coors, Seybold, Merk, Mahler, Ann Allergy Asthma Immunol 2005, 95:593–599 — Polysorbate 80 in medical products and nonimmunologic anaphylactoid reactions
• Rajpar and Shrestha, Contact Dermatitis 2006, 55:119–120 — Severe adverse cutaneous reaction to insulin due to cresol sensitivity
• Carino et al., Ann Allergy Asthma Immunol 2007, 99:194–195 — Delayed-type hypersensitivity reaction to the meta-cresol component of insulin
• Stella and He, Toxicol Pathol 2008, 36:30–42 — Cyclodextrins
• Solensky et al., Ann Allergy Asthma Immunol 2010, 105:259–273 — Drug allergy: an updated practice parameter
• Lieberman et al., Ann Allergy Asthma Immunol 2015, 115:341–384 — Anaphylaxis: a practice parameter update 2015
• Stone et al., J Allergy Clin Immunol Pract 2019, 7:1533–1540 — Polyethylene glycols and polysorbates: two still neglected ingredients causing true IgE-mediated reactions
• Sellaturay et al., J Allergy Clin Immunol Pract 2019, 7:670–671 — Polyethylene glycol-induced systemic allergic reactions
• Pradhan et al., Am J Epidemiol 2022, 191:1352–1367 — GLP-1 receptor agonists and risk of anaphylactic reaction
• Hyman et al., Ann Allergy Asthma Immunol 2023, 130:114–115 — First report of angioedema and anaphylaxis with temporal association to semaglutide
• Lipari et al., JAAD Case Rep 2023, 38:81–84 — Delayed type hypersensitivity injection site reaction and tolerance induction to liraglutide
• Kounis et al., Vaccines 2023, 11:915 — Polyethylene glycol, polysorbate cross-reactivity
• Lawrence et al., Cureus 2024, 16:e52706 — Systemic allergic reaction to tirzepatide
• Calle Sarmiento et al., Cureus 2024, 16:e60879 — Delayed type hypersensitivity reaction induced by liraglutide with tolerance to semaglutide
• Wei et al., Pharmaceutics 2025, 17:1074 — Anti-PEG antibodies and their biological impact on PEGylated drugs
• Wegovy (semaglutide) prescribing information, 2025 — disodium phosphate, sodium chloride, water for injection
• Vyleesi (bremelanotide) prescribing information, 2019 — glycerin, water for injection
• Egrifta WR (tesamorelin) prescribing information, 2025 — hydroxypropyl betadex, mannitol
• Rybelsus (oral semaglutide) prescribing information, 2024 — SNAC, magnesium stearate, microcrystalline cellulose, povidone
• Skytrofa (lonapegsomatropin-tcgd) prescribing information, 2021 — succinic acid, trehalose dihydrate, tromethamine
• FDA MedWatch Safety Information and Adverse Event Reporting Program — Forms 3500 and 3500B
• FDA Adverse Event Reporting System (FAERS) — post-marketing pharmacovigilance database

In-corpus cross-references:

• Peptide storage and stability technical reference — handling chemistry and reconstitution
• Peptide manufacturing technical reference — chemistry-and-controls dossier framework
• Peptide injection technique reference — administration layer
• Antibody development chronic peptide therapy myth — anti-drug antibody pharmacology
• Research-only labeling misframing critic — research-channel regulatory positioning
• Methodology page — site source-grading framework
• Peptide pages cross-linked inline throughout the per-product table and the differential discussion